Pritelivir, also known as AIC-316 and BAY 57-1293, is a potent helicase primase inhibitor. BAY 57-1293 inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound shows profound antiviral activity in murine and rat lethal challenge models of disseminated herpes, in a murine zosteriform spread model of cutaneous disease, and in a murine ocular herpes model. It is active in parenteral, oral, and topical formulations.
Pritelivir (AIC316) is an inhibitor of the viral helicase-primase complex, which exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1].
体内研究
Pritelivir is a pioneering agent in antiviral treatment that interrupts HSV replication by targeting the viral helicase-primase enzyme complex.
Pritelivir, at dosages ranging from 0.03 to 45 mg/kg, significantly improves survival rates and, at 0.3 to 30 mg/kg, reduces mortality against HSV-1, E-377, thereby demonstrating potent and breakthrough antiviral efficiency with the potential for managing life-threatening HSV-1 and -2 infections, including herpes simplex encephalitis.
Compared with the control treatment group, 0.1 or 0.3 mg/kg/ dose of pritlivir combined with acyclovir (10 mg/kg/ dose) had a protective effect against HSV-2 MS strains [3].
搜索
